Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Solvay SA
The company is developing a vaccine with both adenoviral and mRNA technology that could potentially overcome resistance mutations on the SARS-CoV-2 spike protein.
Public Company Edition: The new year started with two companies signaling plans for significant near-term initial public offerings, following Inhibikase’s launch as the last IPO of 2020. Other recent financial highlights include layoffs at Calithera and Regenxbio’s $200m Zolgensma royalty sale.
Following cyberattack, chief information officer Mukesh Rathi said Dr Reddy's was “anticipating all services to be up within 24 hours,” adding that “we do not foresee any major impact on our operations due to this incident.”
Public Company Edition: Outside the US, Zai Lab raised more in its recent Hong Kong initial public offering – $766.4m – than PMV, Prelude, Taysha, Graybug and Greenwich combined. Also, Gilead priced debt to fund its $21bn Immunomedics buy and ADC Therapeutics raised $204m.
- Other Names / Subsidiaries
- Laboratories Ireland Ltd.
- Innogenetics nv